830 related articles for article (PubMed ID: 32796451)
21. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
22. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
23. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
24. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
25.
Cytawa W; Seitz AK; Kircher S; Fukushima K; Tran-Gia J; Schirbel A; Bandurski T; Lass P; Krebs M; Połom W; Matuszewski M; Wester HJ; Buck AK; Kübler H; Lapa C
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):168-177. PubMed ID: 31529265
[TBL] [Abstract][Full Text] [Related]
26. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
27. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
28. Correlation between molecular tumor volume evaluated with
Medina-Ornelas Sevastián S; García-Pérez Francisco O; Hernández-Pedro Norma Y; Arellano-Zarate Angélica E; Abúndiz-López Blanca L
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):223-228. PubMed ID: 29454548
[TBL] [Abstract][Full Text] [Related]
29. [
Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
[TBL] [Abstract][Full Text] [Related]
30.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
31. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
[TBL] [Abstract][Full Text] [Related]
32.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
33. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
34.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of
Afshar-Oromieh A; Holland-Letz T; Giesel FL; Kratochwil C; Mier W; Haufe S; Debus N; Eder M; Eisenhut M; Schäfer M; Neels O; Hohenfellner M; Kopka K; Kauczor HU; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1258-1268. PubMed ID: 28497198
[TBL] [Abstract][Full Text] [Related]
36. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
37. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
38. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
39. Diffuse bone metastases on (68)Ga-PSMA PET-CT in a patient with prostate cancer and normal bone scan.
Lavalaye J; Kaldeway P; van Melick HH
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1563-4. PubMed ID: 27121692
[TBL] [Abstract][Full Text] [Related]
40. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
